---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-048030"
form_type: "8-K"
ticker: "PHGE"
cik: "0001739174"
company_name: "BiomX Inc."
filed_at: "2024-05-30T23:59:59+00:00"
generated_at: "2026-06-01T07:26:13.125165+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.78
calibrated_materiality_score: 0.78
confidence: "high"
source: SEC EDGAR
---

# BiomX receives NYSE American delisting notice for equity deficiency; interim CFO departs

## Summary
- Stockholders' capital deficiency of $9.5M as of March 31, 2024; losses in five recent fiscal years.
- Plan to regain compliance due June 22, 2024; final compliance deadline November 23, 2025.
- Expects to reclassify $32.4M to equity via Series X Preferred conversion at July 2024 shareholder meeting.
- Common stock to trade with '.BC' designation during cure period.
- Interim CFO Avraham Gabay steps down May 31, 2024; CFO Marina Wolfson returns from maternity leave.

## SEC filing metadata
- accession: 0001213900-24-048030
- form_type: 8-K
- ticker: PHGE
- cik: 0001739174
- company_name: BiomX Inc.
- filed_at: 2024-05-30T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.78
- calibrated_materiality_score: 0.78
- confidence: high
- sec_items: 3.01, 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1739174/000121390024048030/0001213900-24-048030-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1739174/000121390024048030/ea020712501-8k_biomxinc.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-048030
- JSON: https://secwatch.observer/filing/0001213900-24-048030.json
- Plain text: https://secwatch.observer/filing/0001213900-24-048030.txt

## Source-grounded claims
- claim_id: 1e2f920599
  claim: Marina Wolfson was appointed as Chief Financial Officer at BiomX Inc..
  evidence_excerpt: following Ms. Marina Wolfson’s return from maternity leave
  evidence_url: https://www.sec.gov/Archives/edgar/data/1739174/000121390024048030/0001213900-24-048030-index.htm
- claim_id: 70629b8d84
  claim: Avraham Gabay departed as Interim Chief Financial Officer at BiomX Inc..
  evidence_excerpt: Effective May 31, 2024, Mr. Avraham Gabay’s term as Interim Chief Financial Officer of the Company will conclude
  evidence_url: https://www.sec.gov/Archives/edgar/data/1739174/000121390024048030/0001213900-24-048030-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.